Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Rent the Runway Inc (RENT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Rent the Runway Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Rent the Runway Inc trades at $3.43 (market cap $113.71M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 350.8× Rent the Runway Inc's market cap. Which is the better fit depends on your goals.
| ALNY | RENT | |
|---|---|---|
Market Cap | $39.89B | $113.71M |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $9.39 |
52-Week Low | $278.09 | $3.10 |
Enterprise Value | $38.15B | $273.81M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Rent the Runway (RENT) trades at $3.35, up 0.6% with a bullish technical signal. The company shows improving fundamentals with 2025 revenue reaching $306.2M and narrowing losses, though negative equity and high debt remain concerns. Recent leadership transition and Q1 2026 revenue growth of 29% indicate strategic shifts. Analyst consensus leans positive with 42% buy ratings but mixed earnings performance.
The outlook suggests potential upside based on low valuation multiples (P/E 0.45, P/S 0.19) and revenue growth trajectory, but risks include persistent negative cash flow, high leverage, and execution challenges under new management. Investors should weigh the discounted valuation against ongoing profitability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →
